2024年11月20日 · 据其新闻稿，JNJ-2113是第一个选择性阻断IL-23受体的靶向口服肽，适用于12岁及以上患有中度至重度斑块状银屑病（PsO）的成人和青少年。 与安慰剂相比，每日一次icotrokinra在患有中度至重度斑块状银屑病的成人和青少年中显示出显著的皮肤清除率。

Major US/EU approvals and submissions and phase 2/3 clinical data presentations being planned or achieved for the year. U.S. patent expiry tables. Information about our Innovative Medicine patent portfolio.

With an outcomes-based design 1 and reduced procedural complexity 2, it’s designed to meet previously unmet surgical needs in hip fracture treatment. The TFN-ADVANCED Nailing System is a part of the Advanced Nailing System from DePuy Synthes and has features that allow surgeons to address proximal femur fractures. The system includes:

11月19日，强生和Protagonist共同宣布, Icotrokinra (JNJ-2113， 前称PN-235 ) 的关键 3 期 ICONIC 研究取得了积极的顶线结果 。 该3期研究在第16周达到了银屑病面积和严重程度指数（PASI）90和研究者整体评估（IGA） 的共同主要终点0/1反应，并且反应率在第24周继续改善。

2024年2月7日 · Investigational JNJ-2113 is the first targeted oral peptide designed to block the IL-23 receptor, 2 which underpins the inflammatory response in moderate-to-severe plaque PsO and other IL-23-mediated diseases. 3,4 JNJ-2113 binds to the IL-23 receptor with single-digit picomolar affinity and demonstrated potent, selective inhibition of IL-23 ...

7月4日，强生在第25届世界皮肤病学大会上公布了口服il-23r抑制剂jnj-77242113（pn-235）治疗中重度斑块状银屑病的ii期frontier 1研究（nct05223868）数据。 点击下载：银屑病领域研究报告

2025年3月3日 · Learn about Johnson & Johnson's extensive portfolio of healthcare products. Find solutions to meet your medical and wellness needs.

2023年7月4日 · SPRING HOUSE, PENNSYLVANIA, July 4, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced positive topline results from its Phase 2b FRONTIER 1 clinical trial evaluating the novel, first and only oral interleukin-23 receptor (IL-23R) antagonist peptide JNJ-2113 in adult patients with moderate-to-severe plaque ...

2024年11月18日，强生Johnson & Johnson宣布Lcotrokinra（研发代号JNJ-2113）用于12岁及以上青少年成人中重度斑块状银屑病（PsO）3期临床试验ICONIC-LEAD达到主要复合终点。

The TFN-ADVANCED™ Proximal Femoral Nailing System (TFNA) is designed to advance hip fracture treatment with an outcomes-based design, reduced procedural complexity, and …